Cartesian Therapeutics, Inc.
RNAC
주식 순위
#18194
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides... Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
주가
$6.44
마지막 동기화: 2026-10-21
시가총액
$194.84M
변동 (1일)
0.70%
변동 (1년)
865.08%
국가
US
거래 Cartesian Therapeutics, Inc. (RNAC)
카테고리
Healthcare
Cartesian Therapeutics, Inc. (RNAC)의 주가 이력
최고 종가: $0.79 (2023-12-01 기준)
최저 종가: $14.00 (2016-06-01 기준)
최저 종가: $14.00 (2016-06-01 기준)
Cartesian Therapeutics, Inc.의 주가 이력 (2016 ~ 2026)
연간 주가 성과
| 연도 | 성과 |
|---|---|
| 2023 | -33.64% |
| 2022 | -62.77% |
| 2021 | 0.01% |
| 2020 | 73.71% |
| 2019 | -58.81% |
| 2018 | -55.20% |
| 2017 | -51.08% |
| 2016 | 0.00% |
유사 기업 또는 경쟁사의 주가
| 회사 | 주가 | 변동률 1년% | 국가 |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $136.29 | -4.85% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $752.87 | 7.01% |
CH
|
